chidamide + fulvestrant

Chidamide (tucidinostat) + fulvestrant is a combination therapy used for hormone receptor-positive (HR+), HER2-negative advanced or metastatic breast cancer. Chidamide is an oral, selective histone deacetylase (HDAC) inhibitor that specifically targets HDAC1, HDAC2, HDAC3, and HDAC10, working through epigenetic regulations to induce cell cycle arrest and apoptosis in tumor cells. It also enhances antibody-dependent cell-mediated cytotoxicity, cytotoxic T cell-mediated anti-tumor immunity, and reverses epithelial-mesenchymal phenotype transformation of tumor cells. Fulvestrant is a selective estrogen receptor degrader (SERD) administered intramuscularly at 500 mg once a month. This combination is primarily used for patients who have progressed after previous endocrine therapy.

Brand names

Epidaza + Faslodex

Other names

chidamide + fulvestrant